ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

avutometinib + defactininb combination

Its studies are mostly in Ovarian Neoplasms, led by Verastem.

Furthest: phase 2, since Jul 15, 20261 company-led study, 1 open or runningNext primary completion: Aug 1, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Verastem11 open or runningphase 2since Jul 15, 2026Jul 15, 2026Aug 1, 2027phase 2 · NCT07747506

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 15, 2026First study: phase 2 study in Ovarian NeoplasmsFirst studyNCT07747506 · 2 planned · France

Ahead

  1. Aug 1, 2027Primary completion: phase 2 study in Ovarian NeoplasmsNCT07747506

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07747506Ovarian Neoplasms · France2Not yet recruitingAug 1, 20272

How it is read

Names in the registry

  • “avutometinib + defactininb combination”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.